CAMP4 THERAPEUTICS CORP
CAMPNASDAQTrading Snapshot
- Day Range
- $3.66 – $3.94
- 52-Week Range
- $2.90 – $7.75
- Volume (shares)
- 55,610
- Avg Volume (shares)
- —
- Shares Outstanding
- 62.8M
- Next Earnings
- 2026-11-04
Fundamentals Snapshot
- Annual Revenue
- $3M
- Last Q Revenue
- $2M
- P/E Ratio
- -1.6
- P/S Ratio
- 54.3x
- EPS (TTM)
- $-1.85
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +166.1%
CAMP4 THERAPEUTICS CORP
CAMP
StockOtter · stockotter.spaceAbout CAMP4 THERAPEUTICS CORP
CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Latest News & Updates
CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union
Approval under the EU Clinical Trials Regulation builds on CAMP4's recent clearances in the United Kingdom, Australia, and Argentina to initiate the Company's global Phase 1/2 trial of CMP-002
CAMP4 Conference: Korro, Tevard Spotlight RNA Fixes for Genetic Disease
Korro and Tevard outlined approaches designed to expand the therapeutic use of RNA medicines beyond protein silencing, highlighting programs that aim to repair genetic defects or restore production of full-length protein
CAMP4 to Participate in Chardan's 10th Annual Healthcare Conference
WATERTOWN, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics desig
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Stock Rated “Moderate Buy” by Wall Street Brokerages
CAMP4 Therapeutics Corporation (NASDAQ: CAMP - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight ratings firms that are covering the stock, MarketBeat Ratings reports. One anal
CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002
CAMP4 Therapeutics (NASDAQ: CAMP) said it expects to dose the first patient in its Phase I/II ASCEND trial of CMP-002 for SYNGAP1-related disorder during the fourth quarter, with top-line results targeted for the first h
Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day Transcript
Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day Transcript